Recurrent refractory arterial thromboembolism associated with the Janus kinase 2 V617F mutation

J Vasc Surg. 2009 Jan;49(1):211-3. doi: 10.1016/j.jvs.2008.07.007.

Abstract

We report two patients with peripheral vascular disease requiring multiple bilateral radiologic and surgical interventions, and whose disease was unresponsive to conventional anticoagulation and antiplatelet therapy. Although thrombocytosis was only intermittent, analysis of the Janus kinase 2 (JAK2) gene revealed a V617F mutation, thus confirming the presence of an underlying occult myeloproliferative disorder. We propose that JAK2 mutation analysis be considered in patients with recurrent, unexplained arterial events to identify those with occult myeloproliferative disorders.

Publication types

  • Case Reports

MeSH terms

  • Anticoagulants / therapeutic use
  • Arterial Occlusive Diseases / enzymology
  • Arterial Occlusive Diseases / genetics*
  • Arterial Occlusive Diseases / therapy
  • Humans
  • Hydroxyurea / therapeutic use
  • Janus Kinase 2 / genetics*
  • Janus Kinase 2 / metabolism
  • Male
  • Middle Aged
  • Mutation*
  • Myeloproliferative Disorders / complications
  • Myeloproliferative Disorders / diagnosis*
  • Myeloproliferative Disorders / enzymology
  • Myeloproliferative Disorders / genetics
  • Myeloproliferative Disorders / therapy
  • Platelet Aggregation Inhibitors / therapeutic use
  • Radiography, Interventional
  • Recurrence
  • Thromboembolism / enzymology
  • Thromboembolism / genetics*
  • Thromboembolism / therapy
  • Treatment Failure
  • Vascular Surgical Procedures

Substances

  • Anticoagulants
  • Platelet Aggregation Inhibitors
  • JAK2 protein, human
  • Janus Kinase 2
  • Hydroxyurea